Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Friedel

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancers|August 10, 2024
Radiosynthesis and Preclinical Evaluation of <sup>18</sup>F-Labeled Estradiol Derivatives with Different Lipophilicity for PET Imaging of Breast CancerAnna Friedel, Olaf Prante, Simone Maschauer
Ecotoxicology and Environmental Safety|August 28, 2018
Changes in social behavior are induced by pesticide ingestion in a Neotropical stingless beeSamuel Boff, Anna Friedel, Rosilda Mara Mussury, et al.
Journal of Clinical Pharmacology|November 9, 2019
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical TrialsAhmed Nader, Sven Stodtmann, Anna Friedel, et al.
Clinical Pharmacokinetics|April 5, 2019
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical TrialsBen Klünder, Rajendar K Mittapalli, Mohamed-Eslam F Mohamed, et al.
Journal of Clinical Pharmacology|April 17, 2019
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFRRajendar K Mittapalli, Sven Stodtmann, Anna Friedel, et al.
Hematological Oncology|June 29, 2019
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysisSuresh Agarwal, Sathej Gopalakrishnan, Sven Mensing, et al.
Journal of Medicinal Chemistry|September 3, 2025
High-Affinity and Proteolytically Stable Peptidic Fluorescent NTS<sub>1</sub>R LigandsFabian J Ertl, Anna Friedel, Elena J Schmid, et al.
Proceedings. Biological Sciences|December 10, 2024
Benefits of extended maternal care in a mass-provisioning bee at the cusp of socialityAnna Friedel, Antonella Soro, Hassan Shafiey, et al.
Journal of Medicinal Chemistry|February 2, 2022
Importance of Binding Site Hydration and Flexibility Revealed When Optimizing a Macrocyclic Inhibitor of the Keap1-Nrf2 Protein-Protein InteractionFabio Begnini, Stefan Geschwindner, Patrik Johansson, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancers|August 10, 2024
Radiosynthesis and Preclinical Evaluation of <sup>18</sup>F-Labeled Estradiol Derivatives with Different Lipophilicity for PET Imaging of Breast CancerAnna Friedel, Olaf Prante, Simone Maschauer
Ecotoxicology and Environmental Safety|August 28, 2018
Changes in social behavior are induced by pesticide ingestion in a Neotropical stingless beeSamuel Boff, Anna Friedel, Rosilda Mara Mussury, et al.
Journal of Clinical Pharmacology|November 9, 2019
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical TrialsAhmed Nader, Sven Stodtmann, Anna Friedel, et al.
Clinical Pharmacokinetics|April 5, 2019
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical TrialsBen Klünder, Rajendar K Mittapalli, Mohamed-Eslam F Mohamed, et al.
Journal of Clinical Pharmacology|April 17, 2019
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFRRajendar K Mittapalli, Sven Stodtmann, Anna Friedel, et al.
Hematological Oncology|June 29, 2019
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysisSuresh Agarwal, Sathej Gopalakrishnan, Sven Mensing, et al.
Journal of Medicinal Chemistry|September 3, 2025
High-Affinity and Proteolytically Stable Peptidic Fluorescent NTS<sub>1</sub>R LigandsFabian J Ertl, Anna Friedel, Elena J Schmid, et al.
Proceedings. Biological Sciences|December 10, 2024
Benefits of extended maternal care in a mass-provisioning bee at the cusp of socialityAnna Friedel, Antonella Soro, Hassan Shafiey, et al.
Journal of Medicinal Chemistry|February 2, 2022
Importance of Binding Site Hydration and Flexibility Revealed When Optimizing a Macrocyclic Inhibitor of the Keap1-Nrf2 Protein-Protein InteractionFabio Begnini, Stefan Geschwindner, Patrik Johansson, et al.
Pageof 1